What "cured of HIV" means in practical terms
A patient cured of HIV has stopped antiretroviral therapy (ART) and maintained undetectable virus without rebound, evidence of sustained remission after a planned, confirmed intervention. This usually follows a hematopoietic stem cell transplant for blood cancer in people living with HIV, not standard HIV care. No approved routine treatment removes HIV from the body; current cures remain complex, high-risk procedures studied in very small numbers. Understanding the difference between remission, control, and cure helps set realistic expectations for people with HIV today.
Key cases that defined the concept of an HIV cure
The Berlin patient (Timothy Ray Brown)
In 2007, Timothy Ray Brown received two hematopoietic stem cell transplants from a donor with a CCR5 delta32 mutation to treat acute myeloid leukemia. After stopping ART, he remained without detectable virus for years, establishing the first documented HIV cure. The therapy was life saving for his cancer but not a feasible approach for HIV alone due to mortality risk.
The London patient
In 2019, reports confirmed a second adult achieved sustained remission after a similar transplant for Hodgkin lymphoma using a CCR5-delta32 donor. The London patient stopped ART with no detectable virus over several years, reinforcing that CCR5 inhibition can contribute to post-transplant remission but again under highly specialized conditions.
The Düsseldorf patient
Published in 2023, the Düsseldorf patient stopped ART after an allogeneic hematopoietic stem cell transplant for acute myeloid leukemia and showed no virologic rebound after an extended follow-up. This case expanded evidence that CCR5-targeted approaches can lead to remission in carefully selected adults treated for concurrent blood cancer.
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Berlin patient | 2007 transplant; CCR5-delta32 donor; ART stopped in 2007; sustained remission documented | Peer‑reviewed case reports and retrospective verification |
| London patient | 2012 transplant; CCR5-delta32 donor; ART stopped in 2017; sustained remission documented 2019 onward | Peer‑reviewed publication and conference data |
| Düsseldorf patient | 2018 transplant; CCR5-delta32 donor; ART stopped in 2018; sustained remission documented 2023 | Peer‑reviewed case report and ongoing follow‑up |
The scientific process behind an HIV cure
An HIV cure typically requires eradicating or controlling all replication-competent virus reservoirs: DNA in the nucleus of resting CD4+ T cells, tissue sanctuary sites, and possibly other sanctuary compartments. Current curative strategies combine:
- Conditioning chemotherapy/radiotherapy to suppress the immune system.
- Hematopoietic stem cell transplantation to rebuild the blood and immune system.
- Selection of a donor with a genetic mutation (CCR5 delta32) that blocks HIV entry into cells.
The goal is a mixed donor–host chimerism in which new immune cells resist HIV infection, and residual host reservoirs are controlled or eliminated over time.
Risks, limits, and why a cure is not standard care
Hematopoietic stem cell transplant carries significant risks, including graft‑versus‑host disease, infections, organ toxicity, and procedure‑related mortality. Because of these dangers, the approach is reserved for life‑threatening blood cancers, not HIV alone. The procedure also requires finding a CCR5‑delta32 donor, conditioning with chemotherapy/radiotherapy, and managing long‑term immune replacement. Current guidelines do not recommend this for people with HIV who do not need a transplant for cancer.
Implications for people living with HIV today
For the vast majority of people with HIV, treatment remains antiretroviral therapy, which suppresses virus replication, protects immune function, and prevents transmission when durably undetectable. A cure remains a research milestone rather than a clinical option. Participation in clinical trials, adherence to ART, and routine care continue to be the proven path to long-term health. Research into cure strategies informs persistence of virus reservoirs, latency mechanisms, and potential future interventions but does not yet change standard care.
What to watch moving forward
Ongoing cure research focuses on safer conditioning, gene editing to create resistance in a patient’s own cells, latency-reversing agents, and immunotherapy approaches. While outcomes in a few cases are encouraging, scalability, safety, and broader applicability remain unproven. Monitoring, methodological rigor, and transparent reporting will determine whether these strategies can evolve into feasible, lower-risk options in the future.